Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer

A 72-year-old man with a history of coronary artery disease requiring angioplasty and 2 stents in 2017 (no history of myocardial infarction and no ongoing cardiac issues) received a diagnosis of National Comprehensive Cancer Network unfavorable intermediate-risk (UIR) prostate adenocarcinoma (Gleason score 4 + 3 in 4 of 12 cores, cT2a, prostate-specific antigen 8.2 mg/L) in October 2019. He refused surgery and met with a radiation oncologist. After prolonged discussions about his prostate cancer risk and his cardiac history, he elected for stereotactic body radiation therapy (SBRT) without androgen deprivation therapy1 and was scheduled for computed tomography simulation in the beginning of March  2020.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research